These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 15505173

  • 1. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Burkhardt RT, Leppik IE, Blesi K, Scott S, Gapany SR, Cloyd JC.
    Neurology; 2004 Oct 26; 63(8):1494-6. PubMed ID: 15505173
    [Abstract] [Full Text] [Related]

  • 2. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Perron R.
    Neurology; 2005 Apr 26; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15858865
    [No Abstract] [Full Text] [Related]

  • 3. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Wiberg CC.
    Neurology; 2005 Apr 26; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15851759
    [No Abstract] [Full Text] [Related]

  • 4. Clinical outcomes associated with brand-to-generic phenytoin interchange.
    Kinikar SA, Delate T, Menaker-Wiener CM, Bentley WH.
    Ann Pharmacother; 2012 May 26; 46(5):650-8. PubMed ID: 22550275
    [Abstract] [Full Text] [Related]

  • 5. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Sherry JH, Bechtel T.
    Neurology; 2005 Aug 23; 65(4):657-8; author reply 657-8. PubMed ID: 16118859
    [No Abstract] [Full Text] [Related]

  • 6. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Stetz SA.
    Neurology; 2005 Aug 23; 65(4):657-8; author reply 657-8. PubMed ID: 16118861
    [No Abstract] [Full Text] [Related]

  • 7. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Rackley RJ.
    Neurology; 2005 Aug 23; 65(4):657-8; author reply 657-8. PubMed ID: 16118860
    [No Abstract] [Full Text] [Related]

  • 8. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Jefferys RJ.
    Neurology; 2005 Aug 23; 65(4):657-8; author reply 657-8. PubMed ID: 16116145
    [No Abstract] [Full Text] [Related]

  • 9. Is bioavailability altered in generic versus brand anticonvulsants?
    Jankovic SM, Ignjatovic Ristic D.
    Expert Opin Drug Metab Toxicol; 2015 Mar 23; 11(3):329-32. PubMed ID: 25440299
    [Abstract] [Full Text] [Related]

  • 10. Double-blind randomized study comparing brand-name and generic phenytoin monotherapy.
    Mikati M, Bassett N, Schachter S.
    Epilepsia; 1992 Mar 23; 33(2):359-65. PubMed ID: 1547767
    [Abstract] [Full Text] [Related]

  • 11. Comparative bioavailability of a generic phenytoin and Dilantin.
    Rosenbaum DH, Rowan AJ, Tuchman L, French JA.
    Epilepsia; 1994 Mar 23; 35(3):656-60. PubMed ID: 8026413
    [Abstract] [Full Text] [Related]

  • 12. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
    Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS.
    Neurology; 2008 Aug 12; 71(7):525-30. PubMed ID: 18695164
    [Abstract] [Full Text] [Related]

  • 13. Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients.
    Tobler A, Mühlebach S.
    Int J Clin Pharm; 2013 Oct 12; 35(5):790-7. PubMed ID: 23812678
    [Abstract] [Full Text] [Related]

  • 14. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
    Contin M, Alberghini L, Candela C, Benini G, Riva R.
    Epilepsy Res; 2016 May 12; 122():79-83. PubMed ID: 26987080
    [Abstract] [Full Text] [Related]

  • 15. Vigabatrin-induced decrease in serum phenytoin concentration does not involve a change in phenytoin bioavailability.
    Gatti G, Bartoli A, Marchiselli R, Michelucci R, Tassinari CA, Pisani F, Zaccara G, Timmings P, Richens A, Perucca E.
    Br J Clin Pharmacol; 1993 Dec 12; 36(6):603-6. PubMed ID: 12959280
    [Abstract] [Full Text] [Related]

  • 16. Phenytoin half-life and clearance during maintenance therapy in adults and elderly patients with epilepsy.
    Ahn JE, Cloyd JC, Brundage RC, Marino SE, Conway JM, Ramsay RE, White JR, Musib LC, Rarick JO, Birnbaum AK, Leppik IE.
    Neurology; 2008 Jul 01; 71(1):38-43. PubMed ID: 18591503
    [Abstract] [Full Text] [Related]

  • 17. Switching between phenytoin generics in patients with epilepsy may lead to increased risk of breakthrough seizure: chart analysis and practice recommendations.
    Shin JW, Chu K, Jung KH, Lee ST, Moon J, Lee SK.
    Int J Clin Pharmacol Ther; 2014 Dec 01; 52(12):1017-22. PubMed ID: 25295717
    [Abstract] [Full Text] [Related]

  • 18. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients.
    Deleu D, Aarons L, Ahmed IA.
    Arch Med Res; 2005 Dec 01; 36(1):49-53. PubMed ID: 15777995
    [Abstract] [Full Text] [Related]

  • 19. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, Krumholz A, Temple R, Polli JE.
    Epilepsia; 2015 Sep 01; 56(9):1415-24. PubMed ID: 26201987
    [Abstract] [Full Text] [Related]

  • 20. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
    Erickson SC, Le L, Ramsey SD, Solow BK, Zakharyan A, Stockl KM, Harada AS, Curtis B.
    Epilepsia; 2011 Jul 01; 52(7):1365-71. PubMed ID: 21692778
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.